Добірка наукової літератури з теми "Chemotherapy biomarker"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Chemotherapy biomarker".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Chemotherapy biomarker"
Bukhari, Ali A., and Ranjit K. Goudar. "Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC." Lung Cancer International 2013 (December 25, 2013): 1–7. http://dx.doi.org/10.1155/2013/436409.
Повний текст джерелаCho, William CS, Timothy TC Yip, Roger KC Ngan, Tai-Tung Yip, Vladimir N. Podust, Christine Yip, Harry HY Yiu, et al. "ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma." Clinical Chemistry 53, no. 2 (February 1, 2007): 241–50. http://dx.doi.org/10.1373/clinchem.2005.065805.
Повний текст джерелаRuddy, Kathryn Jean, Anne M. O'Neill, Kathy Miller, Bryan P. Schneider, Emily Baker, Joseph A. Sparano, Chau T. Dang, Donald W. Northfelt, and George W. Sledge. "Biomarker prediction of chemotherapy-related amenorrhea." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9508. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9508.
Повний текст джерелаChristensen, Ib Jarle, Gunilla Høyer-Hansen, Tine Thurison, Barry Dowell, Julia S. Johansen, Rikke Henriksen, Kristoffer Staal Rohrberg, Nils Brunner, and Hans J. Nielsen. "The prognostic value of seven soluble proteins measured in plasma or serum from patients with colorectal cancer in TNM stages I-III." Journal of Clinical Oncology 30, no. 30_suppl (October 20, 2012): 35. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.35.
Повний текст джерелаMoik, Florian, Sabine Zöchbauer-Müller, Florian Posch, Ingrid Pabinger, and Cihan Ay. "Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer." Cancers 12, no. 6 (June 18, 2020): 1619. http://dx.doi.org/10.3390/cancers12061619.
Повний текст джерелаParks, R. M., L. H. Alfarsi, A. R. Green, and K. L. Cheung. "Biology of primary breast cancer in older women beyond routine biomarkers." Breast Cancer 28, no. 5 (June 24, 2021): 991–1001. http://dx.doi.org/10.1007/s12282-021-01266-5.
Повний текст джерелаAdashek, Jacob, Alexey Goloubev, Shumei Kato, and Razelle Kurzrock. "179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (November 2020): A192. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0179.
Повний текст джерелаChen, Yong-Zi, Youngchul Kim, Hatem H. Soliman, GuoGuang Ying, and Jae K. Lee. "Single drug biomarker prediction for ER− breast cancer outcome from chemotherapy." Endocrine-Related Cancer 25, no. 6 (June 2018): 595–605. http://dx.doi.org/10.1530/erc-17-0495.
Повний текст джерелаDemir, Muzaffer, A. Ciftci, Debra Hoppensteadt, G. Altiay, Mahemut Tobu, Omer Iqbal, Dan Fareed, Cafer Adiquzel, Michelle Kujawski, and Jawed Fareed. "ProteinChip Array Profiling and Markers of Inflammation and Thrombin Generation in Plasma Samples from Lung Cancer Patients and Their Modulation by Chemotherapy with or without Warfarin Anticoagulation." Blood 110, no. 11 (November 16, 2007): 3978. http://dx.doi.org/10.1182/blood.v110.11.3978.3978.
Повний текст джерелаCarcò, Daniela, Paolo Castorina, Paola Guardo, Valeria Iachelli, Tecla Pace, Paola Scirè, Rosaria Stanco, et al. "Combination of Interleukin-6, C-Reactive Protein and Procalcitonin Values as Predictive Index of Sepsis in Course of Fever Episode in Adult Haematological Patients: Observational and Statistical Study." Journal of Clinical Medicine 11, no. 22 (November 17, 2022): 6800. http://dx.doi.org/10.3390/jcm11226800.
Повний текст джерелаДисертації з теми "Chemotherapy biomarker"
Muhammad, Aun. "Microbubble ultrasound as surrogate imaging biomarker for response to systemic and regional chemotherapy." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/44958.
Повний текст джерелаBunting, David Mark. "The performance of circulating biomarkers in the prediction of response to neoadjuvant therapy in patients with oesophago-gastric cancer." Thesis, University of Plymouth, 2016. http://hdl.handle.net/10026.1/6565.
Повний текст джерелаThornton, Michael. "The 78 kDa glucose regulated protein (GRP78) as a potential treatment predictive biomarker and therapeutic target in colorectal cancer adjuvant chemotherapy." Thesis, University of Liverpool, 2014. http://livrepository.liverpool.ac.uk/17993/.
Повний текст джерелаZanjirband, Maryam. "The genomic and functional status of TP53 in ovarian cancer : biomarker for chemotherapy outcome and determinant of response to MDM2 inhibitors." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3831.
Повний текст джерелаAit-Belkacem, Rima. "Caractérisation du glioblastome multiforme et suivi de ses chimiothérapies par imagerie MALDI couplée à l'approche top-down." Thesis, Aix-Marseille, 2014. http://www.theses.fr/2014AIXM5503.
Повний текст джерелаGlioblastoma is the most aggressive of the gliomas, a collection of tumors arising from glia or their precursors within the central nervous system. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 months survival period post-diagnosis. The glioblastoma is characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. In order to optimize the therapy effect, a pharmacokinetic monitoring and a better understanding and characterization of tumor biology are needed. For this purpose, matrix assisted laser desorption/ionization imaging mass spectrometry imaging mass spectrometry (MALDI IMS) technology was applied to identify diagnostic, prognostic and predictive markers of therapy response; and to understand/follow the pharmacokinetic of chemotherapies. The top-down in-source decay strategy was used for protein identification directly on tissue. This strategy allowed tubulin protein isoforms distinction and identification, which is one of the main targets in cancer therapy. MALDI imaging coupled to ISD identified tumorigenesis proteins within tumor structures. Bevacizumab and temozolmide distribution was followed within brain tissue sections. For the first time a monoclonal antibody was deciphered on tissue. Finally, markers that predict therapy response were demonstrated by a comparison between protein expression profiles from tumors with and without chemotherapy treatment. These results highlight the interest of MALDI imaging for chemotherapy improvement and open the way for its use in the clinics
Hendlisz, Alain. "Multimodality imaging for treatment response prediction in colorectal cancer." Doctoral thesis, Universite Libre de Bruxelles, 2015. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209109.
Повний текст джерела1) Le premier projet explore l’imagerie multimodale comme un outil d’individualisation pour la radio-embolisation (microsphères chargées en 90Yttrium) chez des patients porteurs d’un CCR métastatique au niveau du foie, pour laquelle l’imagerie morphologique classique est incapable de mesurer l’effet thérapeutique. Nous montrons que l’usage non sélectif de la radio-embolisation améliore l’histoire clinique de ces patients, bien que certains d’entre eux ne semblent pas en bénéficier. Ensuite, par une analyse multimodale lésion par lésion intégrant angiographie-CT Scan, FDG-PET/CT et scintigraphie aux macro-agrégats d’albumine marqués au 99mTechnetium, nous démontrons que la distribution pré-thérapeutique des macro-agrégats d’albumine est hétérogène entre les différentes lésions des patients et prédictive de la réponse métabolique au sein de ces lésions, permettant le développement d’un outil de prédiction et de planification pour la radio-embolisation.
2) Le deuxième projet explore le domaine du CCR métastatique traité par chimiothérapie palliative. (i) Nous démontrons d’abord que la réponse métabolique (RM) tumorale après une cure de chimiothérapie cytolytique prédit plus vite et plus adéquatement que l’imagerie morphologique basée sur les critères RECIST les bénéfices cliniques du traitement. La RM précoce a une excellente valeur prédictive négative sur l’absence de réponse morphologique et met en évidence une variabilité de réponse inter-lésionnelle chez une proportion importante des patients. (ii) L’étude SoMore explore ensuite des patients présentant un CCR avancé et réfractaire, traités par capecitabine et sorafenib, et confirme l’importance pronostique des RM mixtes, suggérant une méthodologie de classification clinique basée sur la consistance de la RM. (iii) Cette classification cherche confirmation dans l’étude RegARd-C, encore en cours, évaluant les effets du regorafenib, et explorant également la signification génomique et épigénétique de la variabilité de RM.
3) Le troisième projet cherche à utiliser les propriétés de l’imagerie métabolique pour modifier l’algorithme de traitement adjuvant des patients porteurs d’un cancer du côlon de stade III. Ce projet, encore en cours, fait l’hypothèse que l’absence de RM de la lésion primitive après une cure de chimiothérapie prédit l’absence de bénéfice du traitement adjuvant complet. Une analyse intérimaire en démontre la faisabilité et confirme la présence de 40% de tumeurs présentant des caractéristiques métaboliques de chimio-résistance.
En conclusion, pour des patients porteurs d’un CCR, l’imagerie multimodale comprenant une évaluation du métabolisme tumoral permet une évaluation plus précoce et plus adéquate du bénéfice au traitement anticancéreux pour différentes modalités thérapeutiques comme la radio-embolisation, la chimiothérapie cytotoxique et les agents biologiques. L’imagerie multimodale permet de prédire et planifier les radio-embolisations et se révèle très prometteuse pour les traitements chimiothérapiques cytotoxiques ou combinés à des biologiques en situation adjuvante ou métastatique. Elle démontre par ailleurs une importante variabilité de réponse métabolique inter-lésionnelle qui représente un axe de recherche majeur sur les mécanismes moléculaires d’hétérogénéité génomique tumorale et de résistance aux traitements anti-cancéreux.
Doctorat en Sciences médicales
info:eu-repo/semantics/nonPublished
Ferraioli, Domenico. "Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1324/document.
Повний текст джерелаSchlafen 11 (SLFN11) is a putative DNA/RNA helicase, first described for its role in thymocyte development and differentiation in mouse models. SLFN11 is part of a family of proteins with various degree of homology across species, but intriguingly being consistently present only in vertebrates and especially in mammals. Recently, the role of this putative DNA/RNA helicase, SLFN11, was causally associated with sensitivity to DNA damaging agents, such as platinum salts, topoisomerase I and II inhibitors, and other alkylators in the NCI-60 panel of cancer cell lines. In the first study, we validate an anti-SLFN11 antibody in formalin-fixed paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples, developing an immunohistochemistry (IHC) protocol in order to determinate the expression of SLFN11 in our series of HGSOC. Indeed, we tested and validated a reliable SLFN 11 antibody (Ab) in IHC choosing between two anti-SLFN11 Ab used normally for Western Blot (WB) in culture cell block (CCB) of ovarian carcinoma and in an independent series of HGSOCs tissue micro-array (TMA). For each case, we evaluated both the Intensity Score (IS) and the Distribution Score (DS) evaluating at least 300 cells. A Histological Score (HS)was obtained as follow: HS=IS x DS. Successively, we applied our protocol to a large case series of HGSOC samples to confirm our preliminary results. We found one antibody to be reliable in CCB and TMA series allowing to determinate clearly IHC expression of SLFN11. These results were confirmed in our large case series of FFPE HGSOC samples. Briefly, as for TMA independent series, we found that the HS for SLFN11 expression presents a normal distribution with a prevalent (≈ 60%) intermediate expression. Parallel SLFN11 was not expressed in practically 40% of cases that clinically corresponded to the platinum resistant patients in about 60% of cases (16/27). So, we believe that low IHC expression of SLFN 11 should be correlated to response to the platinum-based chemotherapy. In the second study, we investigate the transcriptional landscape of SLFN11 in breast cancer performing a gene expression microarray meta-analysis of more than 7000 cases from 35 publicly available data sets. By correlation analysis, we identified 537 transcripts in the top 95th percentile of Pearson’s coefficients with SLFN11 identifying “immune response”, “lymphocyte activation” and “T cell activation” as top Gene Ontology enriched processes. Furthermore, we reported very strong association of SLFN11 with immune signatures in breast cancer through penalized maximum likelihood lasso regression. Finally, through multiple corresponded analysis we discovered a subgroup of patients, defined “SLF11-hot cluster”, characterized by high SLFN11 levels, estrogen receptor(ER) negativity, basal-like phenotype, elevated CD3D, STAT1 signature, and young age. Using Cox proportional hazard regression, we characterized that SLFN11 high levels, high proliferation index, and ER negativity are independent parameters for longer disease-free interval in patients undergoing chemotherapy. We believe that our second work supports proof of concept that: i) A clear and specific role for SLFN11 in breast cancer, in likely connection with the immune system modulation in such disease entity, ii) a strong correlation between high SFLN 11 and specific molecular subtype of breast cancer (estrogen receptor negativity, basal-like phenotype). Further studies will be performed to confirm our hypothesis in order to: 1) better understand the function of SLFN 11 in cancer cell, 2) validate an easy, reliable and standardized IHC protocol to assessment SLFN11, 3) use SFLN11expression as a predictive biomarker of response to DDA and PARP inhibitors and 4) determinate the relationship with immune system
Nelmes, David-John. "Genetic biomarkers of chemotherapy response and resistance in lung cancer patients." Thesis, Cardiff University, 2018. http://orca.cf.ac.uk/109686/.
Повний текст джерелаBolze, Pierre-Adrien. "Recherche de biomarqueurs prédictifs de l’évolution et de la réponse au traitement dans les maladies trophoblastiques gestationnelles." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSEN016.
Повний текст джерелаHydatidiform moles are a pretumoral placental proliferation which can turn into a tumorrequiring chemotherapy. In order to reduce mortality and propose an optimal therapeuticmanagement, the aim of this thesis is to identify genes which are predictive of postmolartumor transformation and chemoresistance.Concerning the prediction of transformation, the expression analysis of candidate-geneson molar tissue shows a relocalization of Syncytin-1 at the syncytiotrophoblast apicalborder in moles followed by malignant transformation, without modification oftranscription of its receptors and two other retroviral placental envelopes. A wholetranscriptomeapproach using 3 different microarrays-based methods did not identify anydifferentially expressed gene according to the post molar evolution. This may reflect thatinter-individual variability and the different criteria used for tumor diagnosis impede theidentification of robust biomarkers.Concerning the prediction of chemoresistance, a broad-spectrum transcriptomicapproach on choriocarcinoma tumor tissue identifies a down regulation of HLA-G in case of monochemoresistance, confirmed at the protein level by immunohistochemistry.Pathway analysis of the differentially expressed genes suggests thatmonochemoresistance is associated with impaired T-cell differentiation, whereaspolychemoresistance is associated with impaired proliferation of blood cells.Ultimately, the evidence of trophoblastic ubiquitous expression of the PD-L1 immunecheckpoint led us to the evaluation of the efficacy of PD-L1 blockade in chemoresistantpatients. The encouraging results of this trial and the possibility of stratifying patientswith HLA-G and Syncytin-1 markers encourages the assessment of PD-L1 blockadecombined with monochemotherapy as a first line treatment for trophoblastic tumors
Hodgkinson, Victoria C. "The identification of biomarkers of chemotherapy resistance in breast cancer using comparative proteomics." Thesis, University of Hull, 2011. http://hydra.hull.ac.uk/resources/hull:5275.
Повний текст джерелаКниги з теми "Chemotherapy biomarker"
Kim, Kŏn-hong. Yubangam ŭi taje yangmul naesŏng saengchʻe chipʻyo palgul mit kŭ yuyongsŏng kŏmjŭng =: Identification of biomarkers for multidrug resistance and validation of markers in breast cancer tissue. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.
Знайти повний текст джерелаGalderisi, Maurizio, Juan Carlos Plana, Thor Edvardsen, Vitantonio Di Bello, and Patrizio Lancellotti. Cardiac oncology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0064.
Повний текст джерелаPrati, Raquel, and Olga Olevsky. Breast Cancer Staging and Treatment. Edited by Christoph I. Lee, Constance D. Lehman, and Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0012.
Повний текст джерелаЧастини книг з теми "Chemotherapy biomarker"
Ecke, Thorsten H. "Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer." In Advances in Cancer Biomarkers, 293–316. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-017-7215-0_18.
Повний текст джерелаMarti, Francisca E., and Mark P. Saunders. "Chemotherapy and Biomarkers." In Contemporary Coloproctology, 187–200. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-889-8_14.
Повний текст джерелаLaurent-Puig, Pierre, Thierry Lecomte, Marie-Anne Loriot, Valerie Boige, and Helene Blons. "Prediction of Chemotherapy Toxicities." In Biomarkers in Oncology, 249–73. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_10.
Повний текст джерелаChotai, Niketa, and Supriya Kulkarni. "Neoadjuvant Chemotherapy and Biomarkers." In Breast Imaging Essentials, 111–23. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-1412-8_15.
Повний текст джерелаStanisz, Hedwig, Thomas Vogt, and Knuth Rass. "Chemotherapy for Melanoma." In Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma, 247–63. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-60761-433-3_19.
Повний текст джерелаBeyaert, Simon, and Jean-Pascal Machiels. "Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy?" In Critical Issues in Head and Neck Oncology, 193–203. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_13.
Повний текст джерелаStearns, Vered. "Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer." In Biomarkers in Breast Cancer, 129–57. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59259-915-x:129.
Повний текст джерелаCastaneda, Carlos A. "Molecular and Cellular Analyses of Breast Cancers in Real Life." In Improving Oncology Worldwide, 75–82. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-96053-7_10.
Повний текст джерелаRischin, Danny. "Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Critical Issues in Head and Neck Oncology, 83–91. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_6.
Повний текст джерелаIssing, Wolfgang J. "Micronutrients as Intermediate Biomarkers in Chemotherapy and Enhancement for Cancer Treatments." In Primary and Secondary Preventive Nutrition, 55–72. Totowa, NJ: Humana Press, 2001. http://dx.doi.org/10.1007/978-1-59259-039-1_4.
Повний текст джерелаТези доповідей конференцій з теми "Chemotherapy biomarker"
Takeoka, Tomohira, Kumiko Goto, Mitsunobu Matsumoto, Yasuhiro Miyazaki, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, et al. "Abstract B135: Chemotherapy for esophageal cancer: Off-target effect and biomarker." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-b135.
Повний текст джерелаGao, ChongFeng, Luke Wisniewski, Ying Liu, Ben Staal, Ian Beddows, Dennis Plenker, Mohammed Aldakkak, et al. "Abstract PO-002: Detection of chemotherapy-resistant pancreatic cancer using a glycan Biomarker." In Abstracts: AACR Virtual Special Conference on Pancreatic Cancer; September 29-30, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.panca20-po-002.
Повний текст джерелаVodicka, Pavel E., Ludmila Vodickova, Miroslav Svoboda, Jana Slyskova, Barbara Pardini, Alessio Naccarati, and Kari Hemminki. "Abstract 4578: Excision DNA repair: a biomarker of colorectal cancer onset and its chemotherapy." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4578.
Повний текст джерелаKiechle, Marion, Gabriele Schricker, Rudolf Napieralski, Michaela Aubele, Gert Auer, Kurt Ulm, Jonathan Perkins, Stefan Paepke, Moritz Hamann, and Olaf G. Wilhelm. "Abstract P3-08-65: PITX2 DNA methylation: A prognostic/predictive biomarker for anthracycline-based chemotherapy." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p3-08-65.
Повний текст джерелаKwon, Chae Hwa, Sun Jin Lee, Yuri Choi, and Do Youn Park. "Abstract 3365:MAP3K10mutation as a biomarker for predicting response to chemotherapy in gastric cancer patients." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3365.
Повний текст джерелаSohn, Joohyuk, Shuyling Liu, Huiqin Chen, Xiaolong Meng, Kim-Anh Do, Gordon B. Mills, Gabriel N. Hortobagyi, Funda Meric-Bernstam, and Ana M. Gonzalez-Angulo. "Abstract 162: Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT)." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-162.
Повний текст джерелаPataer, Apar, Ruping Shao, Arlene M. Correa, Ignacio I. Wistuba, and Stephen G. Swisher. "Abstract 4527: Major pathologic response and biomarker predict survival in lung cancer patients receiving neoadjuvant chemotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4527.
Повний текст джерелаGowrikumar, Saiprasad, Kristina Pravoverov, Caroline Selisteda, Kiran D. Bastola, Steven Chen, Joshua J. Smith, Mary K. Washington, Amar B. Singh, and Punita Dhawan. "Abstract 3126: A novel biomarker signature in predicting chemoresistance in colorectal cancer: Potential application in chemotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3126.
Повний текст джерелаGowrikumar, Saiprasad, Kristina Pravoverov, Caroline Selisteda, Kiran D. Bastola, Steven Chen, Joshua J. Smith, Mary K. Washington, Amar B. Singh, and Punita Dhawan. "Abstract 3126: A novel biomarker signature in predicting chemoresistance in colorectal cancer: Potential application in chemotherapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3126.
Повний текст джерелаvan Rossum, AGJ, PC Schouten, KE Weber, V. Nekljudova, C. Denkert, G. von Minckwitz, T. Karn, et al. "Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p3-07-28.
Повний текст джерелаЗвіти організацій з теми "Chemotherapy biomarker"
Wang, He, Jun Chen, Xiaoling Wang, and Jun Dang. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0052.
Повний текст джерела